Ignite Creation Date:
2024-05-06 @ 7:36 PM
Last Modification Date:
2024-10-26 @ 3:10 PM
Study NCT ID:
NCT06067347
Status:
RECRUITING
Last Update Posted:
2024-01-24
First Post:
2023-09-05
Brief Title:
A Global Study of the PETAL Consortium
Sponsor:
Organization:
Massachusetts General Hospital
Study Design
Study Type:
OBSERVATIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
True
Target Duration:
4 Years
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
SAMPLES_WITH_DNA
Bio Spec Description:
After careful and centralized review of the archived FFPE lymphoma specimen and immunostains obtained at the time of diagnosis participating pathology investigator at every institution will retain a Hematoxylin and eosin HE and send up to 20 unstained de-identified slides representative of the tumor to BostonGene for NGS including bulk RNA-seq and WES Whenever feasible DNA extracted from mononuclear cells and saliva will be also be sent for NGS as germline control BostonGene will perform NGS and analysis after QC and share raw data and results with the participating investigator of the particular institution that enrolled the specific research participant
We anticipate up to 15 global sites to be participate and enroll in this consortium
Enrollment Count:
1200
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Observational Models:
| Name |
|---|
| Cohort |
Time Perspective List:
Clinical Trial Statuses
| Name |
|---|
| 99683 |
Who Masked List: